IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

膀胱切除术 队列 膀胱癌 泌尿科 医学 临床终点 原位癌 人口 累积发病率 外科 癌症 胃肠病学 肿瘤科 内科学 临床试验 环境卫生
作者
Karim Chamie,Sam S. Chang,Eugene V. Kramolowsky,Mark L. Gonzalgo,Piyush Kumar Agarwal,Jeffrey C. Bassett,Marc A. Bjurlin,Michael L. Cher,William Clark,Barrett E. Cowan,Richard David,Evan R. Goldfischer,Khurshid A. Guru,Mark W. Jalkut,Samuel D. Kaffenberger,Jed C. Kaminetsky,Aaron E. Katz,Alec S. Koo,Wade Jeffers Sexton,Sergei N. Tikhonenkov
出处
期刊:NEJM evidence [Massachusetts Medical Society]
卷期号:2 (1): EVIDoa2200167-EVIDoa2200167 被引量:238
标识
DOI:10.1056/evidoa2200167
摘要

BACKGROUND: Patients with Bacillus Calmette–Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC) have limited treatment options. The immune cell–activating interleukin-15 (IL-15) superagonist Nogapendekin alfa inbakicept (NAI), also known as N-803, may act synergistically with BCG to elicit durable complete responses (CRs) in this patient population. METHODS: In this open-label, multicenter study, patients with BCG-unresponsive bladder carcinoma in situ (CIS) with or without Ta/T1 papillary disease were treated with intravesical NAI plus BCG (cohort A) or NAI alone (cohort C). Patients with BCG-unresponsive high-grade Ta/T1 papillary NMIBC also received NAI plus BCG (cohort B). The primary end point was the incidence of CR at the 3- or 6-month assessment visit for cohorts A and C, and the disease-free survival (DFS) rate at 12 months for cohort B. Durability, cystectomy avoidance, progression-free survival, disease-specific survival (DSS), and overall survival were secondary end points for cohort A. RESULTS: In cohort A, CR was achieved in 58 (71%) of 82 patients (95% confidence interval [CI]=59.6 to 80.3; median follow-up, 23.9 months), with a median duration of 26.6 months (95% CI=9.9 months to [upper bound not reached]). At 24 months in patients with CR, the Kaplan–Meier estimated probability of avoiding cystectomy and of DSS was 89.2% and 100%, respectively. In cohort B (n=72), the Kaplan–Meier estimated DFS rate was 55.4% (95% CI=42.0% to 66.8%) at 12 months, with median DFS of 19.3 months (95% CI=7.4 months to [upper bound not reached]). Most treatment-emergent adverse events for patients receiving BCG plus NAI were grade 1 to 2 (86%); three grade 3 immune-related treatment-emergent adverse events occurred. CONCLUSIONS: In patients with BCG-unresponsive bladder carcinoma in situ and papillary NMIBC treated with BCG and the novel agent NAI, CRs were achieved with a persistence of effect, cystectomy avoidance, and 100% bladder cancer–specific survival at 24 months. The study is ongoing, with an estimated target enrollment of 200 participants (Funded by ImmunityBio.)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嘻嘻哈哈的应助被Chen采纳,获得10
1秒前
1秒前
1秒前
zbw发布了新的文献求助10
1秒前
Hello的应助被www3采纳,获得10
1秒前
无极微光的应助被吐泡泡采纳,获得20
2秒前
赛赛发布了新的文献求助10
2秒前
科目三的应助被zclm采纳,获得10
2秒前
2秒前
2秒前
rgx发布了新的文献求助10
2秒前
庾傀斗发布了新的文献求助10
3秒前
啦啦啦发布了新的文献求助10
3秒前
obcx发布了新的文献求助10
3秒前
3秒前
qq发布了新的文献求助10
4秒前
尹兴亮发布了新的文献求助10
4秒前
zhinian28发布了新的文献求助10
4秒前
口木口木完成签到,获得积分10
5秒前
5秒前
5秒前
zhangxu发布了新的文献求助50
5秒前
思源的应助被开心德地采纳,获得10
5秒前
雪白老头发布了新的文献求助10
5秒前
大模型的应助被阿萍采纳,获得10
5秒前
阔达傀斗完成签到,获得积分20
6秒前
丘比特的应助被Ohhruby采纳,获得10
6秒前
7秒前
闪闪完成签到,获得积分10
7秒前
7秒前
8秒前
山岛完成签到,获得积分20
8秒前
李爱国的应助被冷酷的断缘采纳,获得10
9秒前
大个的应助被橘子090930000采纳,获得10
9秒前
Maestro_S的应助被河马大王采纳,获得30
9秒前
Lucas的应助被霁月采纳,获得10
9秒前
高大抽屉发布了新的文献求助10
9秒前
半三月发布了新的文献求助10
9秒前
zZZ完成签到,获得积分10
9秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187748
求助须知:如何正确求助?哪些是违规求助? 9575825
关于积分的说明 21843288
捐赠科研通 7785628
什么是DOI,文献DOI怎么找? 3435097
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2482000